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Abstract 
Trichomonas vaginalis is the etiological agent of trichomoniasis, the most prevalent non-viral 
sexually transmitted disease worldwide. Trichomoniasis is a widespread, global health concern, and 
occurring at an increasing rate. Infections of the female genital tract can cause a range of symptoms, 
including vaginitis and cervicitis, whilst infections in males are generally asymptomatic. The relatively 
mild symptoms, and lack of evidence for any serious sequelae, have historically led to this disease 
being under diagnosed, and under researched. However, growing evidence that T. vaginalis infection 
is associated with disease states with high morbidity in both men and women has increased the 
efforts to diagnose and treat patients harbouring this parasite. The pathology of trichomoniasis 
results from damage to the host epithelia, caused by a variety of processes during infection, and 
recent work has highlighted the complex interactions between the parasite and host, commensal 
microbiome, and accompanying symbionts. The commercial release of a number of nucleic acid 
amplification tests (NAATs) has added to the available diagnostic options. Immunoassay based Point 
of Care testing is currently available, and a recent initial evaluation of a NAAT Point of Care system 
has given promising results, which would enable testing and treatment in a single visit. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Trichomonas vaginalis is a flagellated protozoan parasite of the human genital tract and the cause of 
the most prevalent curable sexually transmitted disease globally, with an estimated 276.4 million 
cases per year, worldwide (World Health Organisation, 2012). Infections of the female genital tract 
can cause a range of symptoms, including vaginitis and cervicitis (Heine and McGregor, 1993). 
Infections in males are generally asymptomatic, although mild urethritis or prostatitis can occur 
(Guenthner et al., 2005). During the last decade, the discovery that T. vaginalis infection is 
associated with a range of more serious conditions, such as prostate cancer, cervical cancer, adverse 
pregnancy outcomes, and an increased likelihood of HIV infection, has increased the efforts to 
diagnose and treat patients harbouring this parasite (Bachmann et al., 2011). 
Morphology 
T. vaginalis has no cystic stage in its life cycle, existing only as a tear drop shaped trophozoite, with 
an average length and width of 10µm and 7µm, respectively (Petrin et al., 1998). A total of four 
anterior flagella provide the parasite with its characteristic twitching motility, whilst a single 
posterior flagellum, which forms the outer edge of the undulating membrane, runs along the length 
of one side of the cell, assisting in motility and the movement of extracellular nutrients towards the 
cytosome of the cell. The cell also possesses an axostyl, a bundle of microtubules passing through 
the cell along its anterior-posterior axis into the extracellular environment (Lee et al., 2012), which 
has a function in cell attachment and mitosis (Ribeiro et al., 2000). The cytoplasm contains a single 
defined nucleus, and several hydrogenosomes; primitive redox organelles, evolved from 
mitochondria, which produce molecular hydrogen and ATP (Schneider et al., 2011).  
Pathogenesis 
 Transmission occurs almost exclusively via sexual contact, although transmission via fomites has 
been documented, but is rarely encountered and controversial (Schwebke and Burgess, 2004). 
Documented suspected non-sexual transmission routes include shared bathing water (Crucitti et al., 
2011; Burch et al., 1959), and bathing implements (Adu-sarkodie, 1995); routes that are theoretically 
possible due to the ability of the parasite to survive for up to three hours in a moist environment 
(Krieger and Kimmig, 1995). 
During sexual intercourse, T. vaginalis cells in the genital tract of the infected partner are transferred 
to the uninfected partner, and come in to contact with the genital epithelia. When in contact with 
epithelial cells, the typically ovoid T. vaginalis cell morphologically adjusts, assuming an amoeboid 
conformation (Gould et al., 2013). The cells attach to the epithelial surface, with the amoeboid 
morphology enabling the parasite to increase the surface area contact, and interaction, with the 
epithelial cell. T. vaginalis adhesion is largely mediated by a range of iron-dependant surface 
adhesins (Munoz et al., 2012). There are five primary surface adhesins responsible for the 
attachment of the parasite to the host epithelia; AP120, AP65, AP51, AP33, AP23 (Garcia and 
Alderete, 2007). With the exception of AP51, the genes encoding these proteins are all 
transcriptionally upregulated by the presence of iron, which is an essential mediator of T. vaginalis 
growth, and a key factor in virulence (Ryu et al., 2001). Of these surface proteins, AP65 has been 
hypothesised as the most important;  anti AP65 serum IgG antibodies inhibit T. vaginalis 
cytoadherance, which does not occur when the same is carried out on other adhesins (Garcia et al., 
2003). Interestingly, it has been shown that AP65 does not have a covalent anchor motif, and is 
released extracellularly, where it binds to both the T. vaginalis and epithelial cell surface (Garcia and 
Alderete, 2007). The synthesis and transport of these adhesins to the outer membrane occurs in 
response to the contact of the parasite with vaginal epithelial cells, in tandem with a morphological 
shift to the amoeboid form. After adherence, the T. vaginalis cells recruit further parasites to the 
location, forming sizeable aggregates of ameboid cells on the epithelial surface (Arroyo et al., 1992). 
The other primary mediator of cytoadherance to the host epithelia is surface lipophosphoglycan, the 
most highly expressed protein on the T. vaginalis surface membrane (2 x 106 to 3 x 106 copies per 
parasite) (Fichorova et al., 2006), which binds to the galectin-1 protein located on the surface of 
human epithelial cells (Ryan et al., 2011). Site directed mutagenesis studies have shown that T. 
vaginalis cells expressing a lipophosphoglycan molecule with altered surface residues have a greatly 
reduced adherence and cytotoxicity to human vaginal epithelial cells, underlining the importance of 
this molecule for parasite attachment and virulence (Bastida-Corcuera et al., 2005). The 
glyceraldehyde-3-phosphate dehydrogenase, GAPDH, is another protein expressed on the surface of 
T. vaginalis that has been determined to be involved in cytoadherance (Lama et al., 2009). 
The adherence of T. vaginalis to the epithelial cell surface is a crucial factor in pathogenesis; 
adherence of the parasite is cytotoxic, and typically results in the lysis of the host cell, and erosion of 
the epithelial monolayer. This process also instigates the inflammatory response, involving the 
release of chemokines such as IL-8 and the recruitment of neutrophils to infected tissues (Fichorova 
et al., 2006). Damage to the vaginal epithelial monolayer during infection is known to occur via a 
variety of mechanisms, and this contact dependent killing does not involve phagocytosis (Krieger et 
al., 1985). Adherance of T. vaginalis to epithelial cells causes a weakening of the junctional complex 
between individual cells in the epithelial monolayer. This weakening is a result of a decrease in trans-
epithelial electrical resistance, an increase in the gap between neighbouring cells, and also 
modification of the distribution of junction complex proteins, all resulting from the interaction with 
the parasite (Guenthner et al., 2005; da Costa et al., 2005).  
Damage to the host epithelia is also caused by parasite mediated apoptosis of epithelial cells, which 
is dependent on the release of CP30 cysteine proteases (Kummer et al., 2008). This group of 4 
cysteine proteases are also linked to adhesion and the passage of the parasite through the mucosal 
barrier, making them important factors in T. vaginalis pathogenesis.  T. vaginalis is also capable of 
the in vitro phagocytosis of vaginal epithelial cells, leukocytes and erythroyctes, along with 
commensal bacteria (Rendon-Maldonado et al., 1998) and yeasts (Pereira-Neves and Benchimol, 
2007) of the genital tract. Two distinct mechanisms of phagocytosis have been observed during in 
vitro studies with yeasts; a classic form of phagocytosis involving extension of pseudopodia, which 
then engulf the target cell, and also a more passive form, where the target cell sinks into the T. 
vaginalis membrane (Pereira-Neves and Benchimol, 2007). Phagocytosis is followed by intracellular 
killing in lysosomes, and provides the T. vaginalis cell with a source of nutrients (Francioli et al., 
1983). Phagoyctosis is also thought to be the primary route of horizontal gene transfer between 
bacteria and T. vaginalis, providing the parasite with an important mechanism of genetic 
diversification and adaptation (de Koning et al., 2000). The precise mechanisms by which the T. 
vaginalis cells recognise target cells appropriate for phagocytosis is poorly understood, although 
non-specific mannose receptors on the T. vaginalis outer membrane have been implicated in the 
internalisation of yeast cells (Pereira-Neves and Benchimol, 2007). Mannose binding lectins have 
been shown to bind Gram positive and Gram negative bacteria, as well as yeasts, protozoa and even 
some viruses (Klein and Kilpatrick, 2004), showing the wide range of organisms identifiable by the 
presence of this ligand. Mannose is also present on the surface of epithelial cells (Hanada et al., 
2014), leukocytes (Rodriguez-Ortega et al., 1987), and erythroyctes (Lodish, 2000), so T. vaginalis 
mannose receptors may play a part in the recognition of these cell types during phagocytosis or lysis. 
T. vaginalis is known to be able to recognise erythrocytes, and is able to lyse erythrocytes both in 
vitro and in vivo, with haemolysis depending on adherence of the parasite (Fiori et al., 1993). This is 
thought to provide the parasite with a source of iron, an essential nutrient for T. vaginalis growth 
(Ryu et al., 2001).  
Epidemiology and clinical presentation 
The collection of meaningful epidemiological data on T.vaginalis infection is hampered by the fact 
that trichomoniasis is not currently a reportable infection, in developed or developing countries 
(Poole and McClelland, 2013). This means that global and local prevalence and infection rates have 
to be estimated from localised studies, due to the lack of case reporting data available. The most 
recent World Health Organisation (WHO) estimates from data collected in 2008 (World Health 
Organisation, 2012) indicate 276.4 million new cases per year, or 187 million adults infected at any 
one time. This represents a larger number of new infections than those of the next two most 
prevalent STI’s combined, with Chlamydia trachomatis and Neisseria gonorrhoeae infections 
estimated to number 105.7 million and 106.1 million, respectively (World Health Organisation, 
2012). The prevalence and incidence of T. vaginalis infection is geographically variable (Table.1), 
with the highest prevalence found in Africa (20.2% of females, 2% of males), and the Americas (22% 
of females, 2.2% of males). The prevalence in Europe is estimated as 5.8% of females and 0.6% of 
Males.  
The estimated incidence of T. vaginalis is fractionally higher in men than in women, with a male to 
female ratio of total cases globally of 1.14. There is an obvious discrepancy between this fairly equal 
relationship, and the sizeable difference in estimated prevalence rates between the sexes. The 
prevalence of T. vaginalis infection in women is around 10 times higher than in men, irrespective of 
geographic location. This is indicative of the self clearing nature of the infection in males, with the 
majority of persistent infections occurring in females (Van Der Pol, 2007). The higher likelihood of 
persistence in the female genital tract has been linked to the availability of iron, which increases 
during the menstrual cycle, providing the parasite with increased exposure to a major growth 
requirement (Beltrán et al., 2013). The expression of various adhesion proteins promoting 
cytoadherance is enhanced in response to increased iron concentration (Sehgal et al., 2012), and this 
is associated with increased virulence (Ryu et al., 2001). The prevalence of T. vaginalis infection has 
been seen to differ between ethnic populations in the same geographical area, with black females in 
the US having a higher prevalence (10.5%; 95% CI, 8.3-13.3%) than white females (1.1%; 95% CI, 0.8-
1.6%) (Miller et al., 2005). 
T. vaginais infection in females is symptomatic in around 50% of cases, and around 30% of 
asymptomatic cases develop some symptoms in the 6 month period post infection (Rein, 1990). 
Common symptoms include itching and pain during intercourse, a frothy discharge, and vaginitis, 
which can range from mild to severe (Petrin et al., 1998). In acute cases, punctate hemorrhagic spots 
may be present on the vaginal and cervical mucosa, a pathology referred to as colpitis macularis, or 
“strawberry cervix” (Swygard et al., 2004). T. vaginalis infection has also been associated with 
cervicitis, urethritis and also more serious complications such as pelvic inflammatory disease (PID) 
(Heine and McGregor, 1993), cervical cancer (Zhang et al., 1995) and infertility (El-Shazly et al., 
2001). The effects of T. vaginalis infection during pregnancy, and on pregnancy outcomes, are well 
documented. Infections with T. vaginalis at the mid gestation point of pregnancy increases the 
likelihood of a preterm delivery and low birth weight (Cotch et al., 1997). Interestingly, the 
successful treatment of T. vaginalis infection in pregnant women at the mid gestation point does not 
prevent this subsequent preterm delivery (Klebanoff et al., 2001). Neonatal genital and 
nasopharyngeal infections have been reported, with transmission thought to occur during birth 
(Smith et al., 2002).  
Infection of the male genitourinary tract is generally asymptomatic, although mild urethritis, 
epididymitis (Fisher and Morton, 1969), and prostatitis can occur (Guenthner et al., 2005). T. 
vaginalis colonisation of the prostate can lead to chronic infection, and is thought to be the cause of 
most persistent infections in males. Trichomonads have been detected in the prostatic urethra, and 
in the surrounding tissues of the prostate, including the glandula lumina, sub mucosa and stroma 
(Gardner et al., 1986). Until recently, T. vaginalis infection in males was considered a “nuisance 
infection”, without serious consequences (Van Der Pol, 2007). This view has been changed 
somewhat, with the realisation that colonisation of the prostate by T. vaginalis is a risk factor in the 
development of prostate cancer (Sutcliffe et al., 2006). A study involving 673 subjects with prostate 
cancer, and an equal number of control subjects, found a statistically significant association between 
those seropositive for T. vaginalis antibodies, and those with prostate malignancy (Stark et al., 
2009). The increase in risk in developing prostate cancer has been estimated to be between 23% and 
40% (Stark et al., 2009; Sutcliffe et al., 2006). One potential mechanism responsible for the increased 
likelihood of carcinogenesis seen during T. vaginalis infection is the host inflammatory response (Ryu 
et al., 2004), which involves the increase production of pro-inflammatory cytokines that have been 
implicated in prostate malignancy (Azevedo et al., 2011). T. vaginalis infection of has also been 
shown to increase the expression of the proto-oncogene PIM1 in cultured prostate epithelial cells 
(Sutcliffe et al., 2012). PIM1 is also known to induce the expression of another proto-oncogene, 
HMGA1, via the PIM1/c-MYC/HMG1 signalling cascade. Both c-MYC and HMG1 are frequently over 
expressed in malignant prostate cells, and their expression has been linked to increased proliferation 
and metastasis (Sutcliffe et al., 2012). Recent work has shown that T. vaginalis produces a novel 
protein, T. vaginalis macrophage migration inhibitory factor (TvMIF), which has 47% sequence 
agreement with the pro-inflammatory cytokine Human macrophage migration inhibitory factor 
(HuMIF) (Twu et al., 2014). TvMIF inhibits macrophage migration, causes inflammation, and activates 
ERK, Atk, and Bcl-2-associated death promoter phosphorylation, inhibiting with apoptosis and 
causing cellular proliferation. The same study demonstrates that exposure of benign and malignant 
prostate cells to TvMIF in vitro instigates growth and invasion (Twu et al., 2014). 
 
Relationship with other microorganisms 
The presence of T. vaginalis in female patients can cause extensive changes in the vaginal 
microbiome, and trichomoniasis often occurs in tandem with bacterial vaginosis (BV) (Fichorova et 
al., 2013), a condition involving an imbalance in the bacterial flora of the vagina causing vaginal 
inflammation. This imbalance commonly manifests as a reduction in overall numbers of Lactobacillus 
sp., thought to be crucial for the maintenance of vaginal health, in combination with an increase in 
other commensal bacteria that are usually only present in lower levels, such as Gardnerella 
vaginalis, Mobiluncus curtisii, Megasphaera sp., Atopobium vaginae, and Leptotrichia sp. (Fredricks 
et al., 2007). The lactobacilii, predominant in women with a typical vaginal microbiota, contribute to 
vaginal health by releasing lactic acid, which maintains optimal vaginal pH. T. vaginalis grows 
optimally at a pH of 6 to 6.3 (Petrin et al., 1998), whilst the vaginal pH in women with a lactobacilli 
dominated vaginal environment ranges between 2.8 and 4.2 (O'Hanlon et al., 2011). The disruption 
of the lactobacilli community seen during trichomoniasis reduces the lactic acid released into the 
vaginal environment, increasing the pH, and creating more favourable conditions for T. vaginalis 
(Cudmore et al., 2004).  Lactobacilli also act against pathogenic organisms in the vaginal 
environment, by out-competing them for nutrients, and also via the release of hydrogen peroxide, 
which is toxic to a number of potentially BV causing organisms such as Gardnerella vaginalis 
(Klebanoff et al., 1991). BV can have serious health implications, many of which overlap with 
trichomoniasis; increased risk of HIV transmission (Mirmonsef et al., 2012), ascending inflammatory 
infections and preterm birth/low birth weight pregnancy (Taylor et al., 2013). The combination of T. 
vaginalis and BV associated bacteria have been shown to amplify the host immune response, 
including an up-regulation of chemokines such as IL-8, and a down regulation of SLPI, an enzyme 
which protects epithelial cells from serine (Fichorova et al., 2013). SLPI has virucidal effects, and the 
down-regulation of this enzyme, in combination with the damage caused to the epithelial monolayer 
by T. vaginalis, could increased the likelihood of infection with sexually transmitted viral pathogens 
such as HIV and HPV. 
There is a growing body of evidence that suggests T. vaginalis infection increases the chance of the 
acquisition, and transmission of HIV (Mavedzenge et al., 2010).This is of particular concern as T. 
vaginalis is especially prevalent in regions where HIV is considered to be endemic, such as Sub-
Saharan Africa, where 32 million T. vaginalis infections occur each year (McClelland et al., 2007). 
Epidemiological studies have recorded an increase in the risk of HIV-1 acquisition of between 1.52 
and 2.74 fold in T. vaginalis positive women in Sub-Saharan African countries (McClelland et al., 
2007; Mavedzenge et al., 2010; Van Der Pol et al., 2008). A similarly sized increase in the risk of 
transmitting HIV to a serodiscordant partner has also been recorded in T. vaginalis positive women 
in these regions (Sorvillo et al., 2001). The fairly recent realisation of the impact that T. vaginalis 
prevalence has on HIV rates has hastened a greater public health response (McClelland et al., 2007), 
and it is now recognised that the control of T. vaginalis could have a sizeable impact on the 
reduction of HIV transmission in these populations. 
The exact mechanism by which T. vaginalis infection acts to increase the risk of contracting HIV is 
currently undetermined (Thurman and Doncel, 2011), although a number of theories have been 
suggested and tested. T. vaginalis infection instigates a robust mucosal immune response, involving 
localised inflammation and the recruitment of lymphocyctes and macrophages (Fichorova et al., 
2013). This increases the number of potential cells for the virus to invade and proliferate in, and 
would make transmission more likely in a HIV-negative individual.  Additionally, in a HIV-positive 
individual, the increase in cells infected with the virus localised in the genital tract would aid HIV 
shedding during sexual contact, exposing any partners to a higher level of viral particles, facilitating 
transmission (Shafir et al., 2009). HIV positive men with symptomatic urethritis caused by T. 
vaginalis have been shown to have a higher seminal viral load than those with either T. vaginalis 
negative, or with an asymptomatic (Hobbs et al., 1999). Those with symptoms of urethritis will 
necessarily have the greatest level of inflammation, and the greatest levels of CD4 lymphocytes and 
macrophages, increasing the targets for HIV invasion. Additionally, T. vaginalis causes damage to the 
urogenital epithelia, facilitating passage of HIV to deeper layers of the epithelium, and enhancing 
infection (Guenthner et al., 2005).  
One of the more novel intermicrobial relationships of T. vaginalis is the association of the parasite 
with Mycoplasma hominis. This symbiotic relationship, first reported by Nielsen (Nielsen, 1975) was 
the first described association of two obligate human parasites. Co-infection of T. vaginalis with a 
variety of bacterial strains is common, due to the change in vaginal milieu caused by T. vaginalis 
infection, which leads to a favourable growth environment for a number of bacterial species not 
normally associated with the vaginal microbiota. In the case of M. hominis however, the 
mycoplasma has been found to actually enter T. vaginalis cells, surviving and even proliferating 
internally (Vancini and Benchimol, 2008). The presence of M. hominis alongside T. vaginalis has been 
shown to lead to an upregulation of inflammatory cytokines expression in host macrophages in vitro, 
which would potentially increase localised inflammation in vivo (Fiori et al., 2013). Initial concerns 
that infection with M. hominis could be related to metronidazole resistance in T. vaginalis appear 
unfounded (Butler et al., 2010). 
The relationship with M. hominis is not the only symbiotic relationship that occurs involving T. 
vaginalis. The majority of T. vaginalis strains encountered in human infections are infected with one 
or more of a family of four double stranded RNA viruses, from the genus Trichomonasvirus (TVV), 
family totiviridae (Parent et al., 2013). The presence of this virus has been shown to increase 
virulence of T. vaginalis (Parent et al., 2013), in a process hypothesised to involve the modulation of 
parasite gene expression (Goodman et al., 2011). T. vaginalis borne TVV is also recognised by the 
host immune system via its interaction with human toll-like receptor 3 (TLR3), which instigates a pro-
inflammatory cytokine cascade; a process previously linked to increased susceptibility to epithelial 
invasion by HIV (Fichorova et al., 2012). The presence of TVV during trichomoniasis can cause up to 
30 fold amplification of the immune response, increasing the severity of the infection, and risk of 
more serious complications such as PID (Fichorova et al., 2013). It has also been demonstrated that 
this effect is particularly pronounced during simultaneous bacterial vaginosis (Fichorova et al., 2013), 
highlighting that the interaction between the vaginal microbiome, protozoan parasite, associated 
endosimbiant TVV and human epithelial cells has a large bearing on the immune response and 
infection severity. 
Diagnosis  
Female patients 
Trichomoniasis is the most common non-viral sexually transmitted infection (STI) worldwide, with a 
higher prevalence than C. trachomatis and N. gonorrhoeae infections combined (World Health 
Organisation, 2012). Despite this, there is no routine screening programme in place in the UK or US, 
apart from during pregnancy, as there is for C. trachomatis (Workowski and Berman, 2010; Ross, 
2006). This is due in part to the higher incidence of PID and tubal infertility caused by C. trachomatis, 
and also the lower frequency of asymptomatic infection in female patients with trichomoniasis. 
Symptomatic patients in the UK are tested for T. vaginalis, with testing available in the majority of 
GUM clinics. 
The symptoms of T. vaginalis infection overlap significantly with those caused by a number of other 
sexually transmitted pathogens, such as N. gonorrhoea and Mycoplasma genitalium, and a diagnosis 
from clinical presentation alone is rarely possible. The specific symptoms of trichomoniasis, such as a 
the typical inflamed and speckled “strawberry cervix” , and frothy discharge, only occur in a minority 
of around 2% of cases (Fouts and Kraus, 1980), and so cannot be relied upon as a sole indicator of 
the infection. Accurate diagnosis of trichomoniasis is important for the subsequent treatment of 
infection, as antibiotics given for general urethritis treatment such as azithromycin or doxycycline 
are not effective treatments for trichomoniasis (Abdolrasouli et al., 2007).  
Diagnosis of trichomoniasis in female patients is frequently carried out microscopically, by the 
examination of a “wet mount” of vaginal or cervical exudates for motile parasites. This method is 
very simple to carry out, fast, and cost effective, when compared with alternative diagnostic options, 
including culture or molecular methods (Bachmann et al., 2011). Despite these advantages 
microscopic evaluation is not considered the optimal detection method, due to the low sensitivity 
afforded by this technique. Microscopy has been shown to have a sensitivity of around 60%, when 
compared with PCR based methods (Patil et al., 2012). Microscopy is unlikely to detect low level 
infections, in which the organism load in the sample may be under 104 cells/ml, and therefore will 
potentially not be included in the fields examined on the slide (Garber, 2005). The sensitivity of this 
method decreases rapidly if delays are present between sample acquisition and examination, with a 
reduction in sensitivity to 20% caused by a as little as a 10 minute delay reported (Kingston et al., 
2003). Due to this it has been suggested that any diagnostic service which cannot guarantee the 
ability to test samples within an hour of acquisition should use alternative methods (Stoner et al., 
2013). This is of particular concern for clinics that do not operate an on-site microscopy service, and 
rely on the transport of samples to remote centralised laboratories for examination. The reduction in 
sensitivity occurs due to the reduction in parasite motility, making the trichomonads difficult to 
identify. Due to their similar size and shape, T. vaginalis cells can be hard to differentiate between 
lymphocytes when non motile (Garber, 2005).  
The culture of T. vaginalis from clinical samples has long been regarded as the gold standard for the 
diagnosis of this organism (Bachmann et al., 2011). Cultures are typically maintained in a broth 
medium, and inoculated with swab samples taken from the vaginal canal or cervix of female 
patients, or urethral discharge from male patients. Cultures can also be inoculated from urine 
samples, although this is not the optimal sampling method, and reduced sensitivity. Growth can be 
apparent in as little as 48 hours, but cultures should be incubated for at least 7 days to enable the 
detection from low inocula (Garber, 2005). 
The most common media used are variants of Diamonds (TYM) medium (Diamond, 1957), which 
originally contained trypticase digest, yeast extract, maltose, cysteine, ascorbic acid and sheep 
serum. Possibly the most frequently used variant is Diamonds TYI-S-33 medium, which also contains 
a source of iron, foetal bovine serum in place of sheep serum, and a vitamin 107-Tween 80 mixture 
(Diamond et al., 1978). T. vaginalis is incapable of synthesising a range of macromolecules necessary 
for survival and growth, including purines, pyrimidines and some lipids, and relies on nutrients 
acquired from secretions or phagocytosed human or bacterial cells in the host genital tract. This 
necessitates the presence of these molecules in any culture media, and serum especially is a key 
component to support axenic growth of this organism (Petrin et al., 1998). 
The use of broth culture to diagnose T. vaginalis infection has a higher diagnostic sensitivity than 
wet mount microscopy. One study of 337 samples, including 97 positive samples, found microscopy 
and culture had sensitivities of 52% and 78% respectively (Wendel et al., 2002). However, the use of 
culture to diagnose trichomonas infection does have some significant disadvantages. The week long 
incubation required means that culture is the diagnostic option with the longest time between 
sample acquisition and result. Additionally, culture is less sensitive than molecular methods, such as 
PCR. The use of solid media to culture T. vaginalis has been reported in the literature (Stary et al., 
2002), although is rarely used in a clinical diagnostic setting. One study found a solid modified 
Columbia agar medium to be more sensitive (98.4%) than a commercially available Trichomonas 
medium (92.1%) (Stary et al., 2002). 
One commercially available culture based diagnostic test is the InPouch culture system (Biomed 
Diagnostics, USA). This system combines both culture and microscopy to provide a diagnostic 
solution that offers the advantages of both methods (Sood et al., 2007). It consists of a clear plastic 
pounch containing two conjoined chambers full of media, one of which is inoculated via a swab. The 
other chamber is thinner, and has a thin viewing window enabling examination for any 
trichomonads using microscopy. This method has been shown to be more sensitive than wet-mount 
microscopy alone (Draper et al., 1993; Sood et al., 2007), and also removes the need for a pre 
culture transport medium, as the pouch is inoculated directly from the patient, which improves the 
likelihood of a successful culture (Schwebke et al., 1999). The fact that microscopic evaluation of the 
culture can be carried out without any fluid manipulation removes the possibility of contamination 
and reduces the time taken during the examination. This method is more expensive than standard 
culture or microscopy based methods however (Draper et al., 1993). 
Serological methods for diagnosing T. vaginalis have been developed, but are rarely used clinically. A 
monoclonal antibody based enzyme-linked immunosorbant assay (ELISA) test specific to T. vaginalis 
surface peptides has been shown to offer sensitivities and specificities of 89% and 98% compared 
with broth culture (Lisi et al., 1988). A detection limit of 100 trichomonads per ml, and a greater 
sensitivity than wet mount microscopy, has been demonstrated using another ELISA assay (Watt et 
al., 1986). The Trichomonas Direct Enzyme Immunassay (California Integrated Diagnostics, US), was a 
commercially released ELISA test, which is no longer on the market. It relied on a mix of peroxidase 
labelled monoclonal antibodies to an assortment of T. vaginalis proteins, and was as sensitive as 
broth culture (Petrin et al., 1998). One immunoassay currently available commercially, and the only 
T. vaginalis immunoassay currently awarded FDA approval in the US, is the OSOM Trichomonas 
Rapid Test (Sekisui Diagnostics, US). The test is an immunochromatographic  capillary flow dipstick 
test, and provides a result within 10 minutes, enabling it’s use at point of care (POC). The OSOM test 
has a sensitivity and specificity of 82% and 97% respectively (Huppert et al., 2007), making it a more 
sensitive diagnostic test than wet-mount microscopy, culture, and standard ELISA methods, whilst 
being far quicker and simpler to carry out. 
Both commercial, and “in house” PCR based assays for T. vaginalis are available, and provide a more 
sensitive form of testing than the traditional methods of wet-mount microscopy and culture. 
Although PCR requires more highly trained staff and more expensive equipment and reagents, than 
alternative methods, the sizeable increase in sensitivity, coupled with a relatively short turnaround 
time,  makes PCR based assays the optimum diagnostic method in developed countries. A range of 
genes have been exploited as targets for T. vaginalis specific PCR tests. A standard PCR assay specific 
to a sequence of the beta-tubulin gene was found to have a sensitivity and specificity of 97% and 
98% respectively (Madico et al., 1998). The same study found the sensitivities of wet mount 
microscopy and culture to be 36% and 70% respectively, illustrating the improvement in sensitivity 
offered by PCR. A study comparing the sensitivity of two real-time fluorescence resonance energy 
transfer (FRET) hybridisation probe based PCR assays specific to the beta-tubulin gene and 18S rRNA 
gene found assay sensitivities of 96% and 100% respectively (Simpson et al., 2007). The T. vaginalis 
genome harbours a number of conserved repeated DNA sequences, and these are attractive targets 
for nucleic acid amplification tests (NAATs), as they provide a higher copy number per cell, and 
improve detection limits and sensitivities (Bandea et al., 2013). The sequencing of the ~160 Mb T. 
vaginalis genome identified 59 common repeat families that make up ~39 Mb of the complete 
sequence (Carlton et al., 2007). The majority of the repeat sequences have a copy number of >100, 
with the average being 660 copies. Importantly, these repeats show a high level of homogeneity, 
with sequence variation identified between repeats of the same family in only 2.5% of repeats. This 
provides a stable, high copy number target for molecular assays. Single parasite detection has been 
demonstrated for PCR assays using these repeated sequences as targets (Kengne et al., 1994), and 
the improved sensitivity has enable testing from non-invasive urine samples, which typically contain 
a lower organism load than the swab samples more frequently used (Bandea et al., 2013). 
The overwhelming majority of NAATs available for T. vaginalis identification are PCR based, however 
novel isothermal diagnostic methods have been applied to the detection of this organism. The 
commercially available APTIMA T. vaginalis assay (Gen-Probe, US), relies on transcription mediated 
amplification technology, in combination with a target capture specimen processing system, to 
provide a highly sensitive assay for T. vaginalis detection (Chapin and Andrea, 2011). The assay is 
designed to be used on one of the automation systems available from Gen-Probe, such as the 
TIGRIS. The assay is approved for use in the US by the Federal Drug Administration (FDA), and is 
approved for use in the UK. The approval only relates to the use of the assay with a number of 
sample types from female patients, including urine samples, endocervical swabs, and vaginal swabs. 
GenProbe also manufactures AMPTIMA assays for other sexually transmitted pathogens, including 
N. gonorrhoeae, human papillomavirus (HPV), and a combined C. trachomatis and N. gonorrhoeae 
assay (APTIMA COMBO 2 assay). A large scale study of 933 symptomatic and asymptomatic female 
patients attending an STI clinic found the APTIMA assay to have the following sensitivity and 
specificity, respectively, in the following samples types; 100% and 99.0% for vaginal swabs, 100% 
and 99.4% for endocervical swabs, and 95.2% and 98.9% in urine specimens (Schwebke et al., 2011). 
Another commercially available molecular diagnostic test for T. vaginalis infection is the Affirm VPIII 
Trichomonas vaginalis assay (Becton Dickinson, US), which relies on RNA probe hybridisation to 
detect target DNA.  The test has been shown to be more sensitive than wet mount microscopy 
(Brown et al., 2004), but lacks sensitivity compared to NAATs, as the target DNA is not amplified 
before detection, which results in a higher starting copy number being required in order to generate 
signal. One study compared the Affirm VPIII assay with the APTIMA assay, and found sensitivities of 
63.4% and 100% respectively (Chapin and Andrea, 2011). The test is fully automated, and takes 45 
minutes to run, including 2 minutes “hands on time”, potentially enabling point of care testing. 
POC testing for sexually transmitted infections, including trichomoniasis, could be of great benefit in 
the control of these diseases (Tucker et al., 2013). Testing at the POC enables consultation, testing, 
and the provision of appropriate treatment to all be carried out in the same day, at the same site. 
This removes the risk of patients neglecting to return for results and medication, and also reduces 
the possibility of transmission by sexual contact during the delay before treatment is instigated 
(Tucker et al., 2013). Currently, it is possible to carry out testing via wet mount microscopy at POC, 
although this is insensitive, low throughput, and effected by the experience and skill of the 
technician. Also, the immunochromatographic  OSOM Trichomonas Rapid Test (Sekisui Diagnostics, 
US) is able to provide results within 10 minutes, is easy to use and read, and has higher sensitivity 
than non-molecular methods (82% compared with PCR), making it a very good option for providing a 
POC diagnostic (Huppert et al., 2007). The current goal of POC diagnostic research is to provide the 
sensitivity of NAAT diagnostics, whilst eliminating hands-on processing, and decreasing the time-to-
result, enabling maximally sensitive testing at the point of care (Craw and Balachandran, 2012). The 
majority of POC NAAT systems in development rely on an automated nucleic acid procedure, rapid 
target amplification, and detection of reaction products, typically by optical detection of 
fluorescence (Niemz et al., 2011). These processes are often carried out in a disposable single use 
cartridge or chip, preventing contamination of the machine during sample handling (Niemz et al., 
2011).  One such system currently in development is the Atlas Io PoC (Atlas Ltd, UK) platform, which 
is aiming to release a Trichomonas vaginalis test in 2014. The test involves automated nucleic acid 
extraction, followed by amplification of a multi-copy DNA repeat sequence target, and novel 
electrochemical endpoint detection. A small scale lab evaluation of the test, comparing its 
performance with that of the APTIMA T. vaginalis test (Hologic Gen-Probe, USA), over 90 clinical 
samples, found that the sensitivity and specificity of the assay were 95.5% and 97.5% respectively 
(Pearce et al., 2013). The most widespread commercially available POC system is the GeneXpert 
(Cepheid, USA), a platform for processing real-time PCR based assays with fully automated sample 
preparation, amplification and detection on disposable assay-specific cartridges (Helb et al., 2010). 
Currently there are FDA approved GenExpert assays available for Mycobacterium tuberculosis 
(Marlowe et al., 2011), Clostridium difficile (Babady et al., 2010) and a combined C. trachomatis and 
N. gonorrhoeae assay (Tabrizi et al., 2013), all of which have high sensitivities and specificities, and 
provide results within 90 minutes. Cepheid has announced that it plans to release a T. vaginalis 
assay in the 2014-2015 product range, enabling testing for trichomoniasis to be carried out using this 
platform. 
The use of POC testing for trichomoniasis could be of particular benefit in sub-Saharan Africa, where 
both T. vaginalis and HIV infection are highly prevalent. The improved control of T. vaginalis could 
potentially reduce HIV transmission, and significantly impact on morbitity and mortality in the region 
(Johnston and Mabey, 2008). POC testing has been regarded as being particularly well suited to 
developing countries, as the automated POC systems reduce the need for skilled technicians, or well 
equipped centralised laboratories, which may not be widely available (Pai et al., 2012). Additionally, 
the ease of transport, and lack of additional equipment needed by these systems, enables the 
testing of remote communities, far removed from traditional hospital based healthcare. However, 
concerns remain over whether the expense of POC NAAT systems will prevent their widespread use 
in developing countries, with studies examining the prospective cost of implicating widespread POC 
NAAT testing in Africa highlighting the increased cost of diagnosis (Meyer-Rath et al., 2012). Field 
testing of the Cepheid GenExpert C. trachomatis assay in South Africa has given promising results, 
demonstrating high clinical sensitivity in combination with being well suited for use outside of the 
traditional laboratory environment (Jenson et al., 2013), and the GenExpert M. tuberculosis assay is 
already being widely used in sub-Saharan Africa (Osman et al., 2014; Lawn et al., 2013). As use of the 
GenExpert system is becoming more widespread in developing countries, especially for detecting M. 
tuberculosis, it is possible that healthcare providers may take advantage of the platform to diagnose 
T. vaginalis, upon the predicted release of the assay in 2015. 
Male patients 
The diagnostic testing for T. vaginalis infection in male patients is rarely undertaken, for a number of 
reasons. T. vaginalis infection in men is rarely symptomatic, and male partners of women who have 
received a positive diagnosis are treated concurrently without any confirmatory testing (Schwebke 
and Lawing, 2002). Microscopy of urethral discharge, if present, has a poorer sensitivity with male 
samples than females. Culture can be undertaken from male samples, and the optimal sample type 
is considered to be a combination of urethral swabbing and collection of urine sediment however, as 
with microscopy, sensitivity is poor (Krieger et al., 1993). The low organism loads encountered in 
male patients mean that sensitive, molecular methods are required in order to provide an 
acceptable level of sensitivity, if testing for T. vaginalis infection is going to be carried out. 
In the past T. vaginalis infection in males has often been considered to be a nuisance infection, due 
to the fact that the infection in males is self-limiting, typically clears without intervention, and the 
belief that infection in males rarely results in any serious sequelae (Van Der Pol, 2007). There is 
growing evidence to the contrary; that infection in males can lead to chronic colonisation (Lee et al., 
2012), and that it may be a causative agent in prostate cancer (Sutcliffe et al., 2006). It has been 
shown conclusively that T. vaginalis increases the transmission of sexually transmitted viruses, 
including HIV (Sorvillo and Kerndt, 1998; Mavedzenge et al., 2010), which in itself makes the control 
of this organism in males a non-trivial matter. The increasing realisation that this organism is 
associated with disease states with high morbidity in both men and women, and can have serious 
detrimental effects on reproductive health has lead to an increased interest for diagnosis and 
treatment of infections (Soper, 2004), and the treatment of males inevitably will play a part in this 
process. This is driving the need for sensitive, molecular based approaches for the detection of this 
organism. 
Treatment 
The standard treatment for T. vaginalis infection, in the UK and worldwide, is a single 2g oral dose of 
metronidazole or tinidazole (Muzny and Schwebke, 2013). The most commonly administered drug in 
the UK is metronidazole, in part due to the low associated cost(Sherrard et al., 2014). These 
antibiotics from the 5-nitroimidazole family exert their antimicrobial activity by disrupting the redox 
system of the parasite, with metabolic products of the drug binding to proteins in the thioredoxin 
mediated redox network and inhibiting thioredoxin reductase (Leitsch et al., 2009). The 
antimicrobial properties of these drugs rely on reduction at the nitro group, which occurs after 
passive diffusion of the drug into the hydrogenosome of the cell, generating nitroradical anions, and 
further reduced reactive intermediates (Dunne et al., 2003).Whilst in bacterial cells these 
nitroradicals would cause DNA damage, and cell death, the precise mechanism of by which they 
damage eukaryotic microorganisms is poorly understood (Kulda, 1999). 
Of the available 5-nitroimidazole drugs, tinidazole is considered the optimal antimicrobial agent, 
with numerous studies showing that tinidazole therapy has either an equal or lower failure rate than 
metronidazole therapy (Bachmann et al., 2011). A large scale study reviewing the outcomes of 
female patients receiving different therapies found the clinical failure rate of those taking 
metronidazole to be 14.8%, compared with a 3.7% failure rate for those receiving tinidazole 
(Bachmann et al., 2011). This is partly explained by the ~12.5 hour half-life of tinidazole being ~70% 
longer than that of metronidazole, and its higher serum concentration (Bachmann et al., 2011). 
Resistance to 5-nitroimidazole class drugs has been encountered in clinical T. vaginalis isolates, in 
particular resistance to metronizadole, which is the antimicrobial that has historically seen the 
greatest use in the treatment of this organism. The overall prevalence of resistance is low; a study of 
538 isolates from a number of clinical sites in the US found low level metronizadole resistance in 
4.3% of isolates, and no resistance to tinidazole (Kirkcaldy et al., 2012). The prevalence of 5-
nitroimidazole resistance in developing countries does not appear to be any greater than in 
developed countries; studies in Africa have found the prevalence to be 6% (Rukasha et al., 2013). 
Due to the lack of effective alternative approved treatments for T. vaginalis infection, the only 
available treatment for a metronizadole resistant infection is to increase the dosage, to a potentially 
toxic and side effect inducing level, or alternatively use tinidazole (Cudmore et al., 2004). 
Conclusion 
The pathogenic effect caused by colonisation of the genital tract by T. vaginalis is caused by damage 
to the epithelia of the genital tract, which the parasite causes in a variety of ways, including 
mechanical damage, the secretion of apoptosis inducing proteases, the disturbance of the junctional 
complexes in the monolayer, and the instigation of an inflammatory response. The virulence of the 
infection, and disease severity, is similarly complex, and governed by a range of factors. Infection of 
the female genital tract is capable of significant modification of the vaginal microbiome, potentially 
resulting in bacterial vaginosis, worsening the symptoms of the infection (Fichorova et al., 2013). As 
well as organisms present in the vaginal environment, T. vaginalis infection can be impacted by the 
presence of the intracellular symbionts  M. hominis or TVV, which modulate T. vaginalis gene 
expression in a process thought to increase virulence (Fichorova et al., 2013; Fiori et al., 2013; Fraga 
et al., 2012).  
T. vaginalis infection is most common non-viral STI worldwide; only genital human papillomavirus 
(HPV) is more prevalent (Bruni et al., 2010) . There are an estimated total number of 276.4 million 
cases per year world-wide, more than the 106.1 million new cases of N. gonorrhoeae infection, and 
105.7 new C. trachomatis infections combined (World Health Organisation, 2012). T. vaginalis 
infection is a widespread, global concern, prevalent in Europe (5.8%), the Americas (22%) and Africa 
(20.2%). The high prevalence of T. vaginalis infection in Africa is of a particular concern, as the 
parasite has been implicated in increasing the likelihood of both becoming infected by, and 
transmitting, HIV (Mavedzenge et al., 2010). Despite the high frequency, and ubiquitous geographic 
spread of this disease, it has received a much smaller public health response than the next most 
prevalent curable STI’s, C. trachomatis and N. gonorrhoeae (Van Der Pol, 2007). This has been due in 
part to the consideration of trichomoniasis as a mild “nuisance” infection, compared with the more 
serious tubal infertility risk associated with chlamydia infections in women, and the obvious 
symptoms caused by gonorrhoea. Growing evidence that T. vaginalis infection can increase the risk 
of disease states associated with high morbidity in both male and female patients is increasing the 
interest in the detection and treatment of this parasite. The development of sensitive NAAT tests for 
T. vaginalis has opened up the possibility of testing asymptomatic patients, who often have low 
organism loads, undetectable with less sensitive diagnostic methods. In the UK, the cost of offering 
this service in a sexual health screen is thought to outweigh the benefit of detecting these 
asymptomatic infections, due to the relatively low prevalence of this organism in the general 
population (Ng and Ross, 2012). However, in the US, where the prevalence is much higher, this could 
be a viable strategy. The testing of males, who tend to have a lower organism load, by traditional 
methods such as microscopy or culture, is less sensitive than in females, and the increased sensitivity 
afforded by NAATs allows for the sensitive testing of this group. The continuing development and 
improvement of POC NAAT testing, and the imminent release of T. vaginalis assays for existing POC 
platforms, will provide the opportunity for the provision of sensitive rapid testing for this organism, 
with all the inherent benefits of testing at the POC. 
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Tables 
WHO Region 
Incidence (per 1000) Prevalence (%) 
Female Male Female Male 
Africa 146.0 164.8 20.2 2 
The Americas 177.7 180.6 22.0 2.2 
South East Asia 40.3 50.1 5.6 0.6 
European 51.7 48.4 5.8 0.6 
Eastern 
Mediterranean 
64.0 66.1 8.0 0.8 
Western Pacific 45.6 47 5.7 0.6 
Table 1. Global incidence and prevalence of T. vaginalis infection, according to 2012 WHO estimates. 
Data taken from World Health Organisation, 2012. 
 
